In Brief: The Liposome Company TLC D-99
The Liposome Company TLC D-99: Pfizer returns rights to the liposomal doxorubicin product to TLC on July 14; Pfizer will receive royalties on any sales of the product, which is in Phase III trials in metastatic breast cancer patients as a lower-cardiotoxicity alternative to conventional doxorubicin. TLC is attempting to reinvigorate its pipeline after the failure of its acute respiratory distress syndrome therapy Ventus in a Phase III trial ("The Pink Sheet" June 30, In Brief). TLC has let go of 110 employees, bringing its total headcount to about 300...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth